Panbela Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 6.49 million compared to USD 4.73 million a year ago. Basic loss per share from continuing operations was USD 65.9. Diluted loss per share from continuing operations was USD 65.9.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4401 USD | -8.31% | +15.88% | -97.60% |
05-17 | North American Morning Briefing : The "Everything -2- | DJ |
05-15 | Transcript : Panbela Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.60% | 2.14M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- SNBP Stock
- News Panbela Therapeutics, Inc.
- Panbela Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023